Rapastinel
Phase 3Small molecule
AbbVieRapastinel is one of 85 small molecule programs targeting Major Depressive Disorder. It is currently in Phase 3.
2
Indications
15
Total Trials
0
Active Trials
84
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
386 competitors in Major Depressive Disorder
#DrugCompanyPhaseTrials
1Nuplazid
AACADIA Pharmaceuticals Inc.
Phase 3
Ketalar
Boehringer IngelheimPhase 3
Lisdexamfetamine Dimesylate
TakedaPhase 3
Bupropion XL
GSKPhase 3
SPD489
TakedaPhase 3
Venlafaxine ER
PfizerPhase 3
MK0869, Aprepitant
Merck & Co.Phase 3
Antidepressant Therapy
AbbViePhase 3
Saredutant
SanofiPhase 3
Vraylar
AbbViePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Major Depressive Disorder10 trials
Show 7 more trials
Obsessive-Compulsive Disorder1 trial
1 more indication
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Rapastinel. EMBL-EBI & Wellcome Sanger Institute.
- [4]